meaning jump await
 cost could continu surpris street set expect
low opinion
regeneron expens guidanc surpris investor although
view invest benefici long-term despit short-term pain howev
increas spend may persist due on-going earli pipelin program
libtayo develop cost higher clinic manufactur cost higher headcount
regeneron guid toward non-gaap unreimburs high end
rang estim spend could higher
believ higher spend yield return futur despit near-term
us eylea beat consensu estim vs consensu
estim importantli inventori declin slightli
posit although discount rebat increas continu expect higher
discount rebat addit competit enter wet market
cautiou upsid eylea diabet retinopathi due asymptomat
present mani patient may go see physician potenti
competit space also patient requir treatment undergo laser therapi
first despit impress data eylea regeneron need overcom
see death due
manag mention death due high degre
use combin immunotherapi concern total
unexpect cyutokin releas syndrom seen bispecif cart
product target regeneron look lower dose either
and/or libtayo may improv safeti maintain efficaci look addit
detail eha note relapsed/refractori follicular lymphoma diffus larg
b-cell lymphoma competit space rituxan establish long-term
maintain hold lower pt base much higher spend
maintain hold rate lower pt base much higher
 spend expect exceed compani guidanc note higher spend
rel inescap matter earli pipelin develop libtayo
develop cost higher clinic manufactur cost higher headcount
cost continu expect strong growth dupix moder growth
eylea signific increas spend bit surpris
price close busi may
biotech discov
invent manufactur commerci medicin
treat seriou diseas
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
hold unchang target price may
date eylea npdr patient w/o dupix chronic rhinosinus nasal non-gaap epsp multipl figur revenu build
hold unchang target price may
revenu producteyleau ex-u arcalystu ex-u revenues- libtay ex-u revenues- net product sale book praluentu ex-u ww zaltrapww us ex-u kevzarau ex-u us atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price may
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sell gener collabor total oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli epsbas share dilut share outstand figur balanc sheet
hold unchang target price may
regeneron pharmaceut balanc sheetasset cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens capit leas oblig defer revenu sanofi current portion defer revenu current portion facil leas oblig current portion current liabilities- total current liabil convert senior notes- defer revenu sanofi defer revenu facil leas oblig long term liabil total liabil figur statement
hold unchang target price may
statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict cash- flow repurchas repay note payable- proce connect facil leas obligations- payment connect facil leas obligations- net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end paid interest paid incom tax
